Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 8/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.36 |
| ▸ | MAT2A | P31153 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18645412 | 0.91 | PIK3CA (0.41) | PIK3CAPIK3CBPIK3CGPIK3CDLMNA | |
| SCHEMBL18614458 | 0.89 | PIK3CA (0.38) | PIK3CAPIK3CBPIK3CGPIK3CD | |
| SCHEMBL19751544 | 0.81 | PIK3CA (0.37) | PIK3CAPIK3CBPIK3CGPIK3CDMAT2A | |
| SCHEMBL15828690 | 0.77 | MAT2A (0.34) | PIK3CAPIK3CBPIK3CGMAT2A | |
| SCHEMBL19737444 | 0.77 | MAT2A (0.35) | PIK3CAMAT2A | |
| SCHEMBL30096583 | 0.73 | PARP1 (0.44) | PIK3CAPIK3CBLMNAHTT | |
| SCHEMBL18614457 | 0.72 | DRD2 (0.31) | — | |
| SCHEMBL18645843 | 0.69 | PIK3CA (0.52) | PIK3CAPIK3CBPIK3CGPIK3CD | |
| SCHEMBL18614460 | 0.69 | PIK3CA (0.44) | PIK3CAPIK3CBPIK3CGPIK3CDLMNA | |
| SCHEMBL29549652 | 0.67 | PARP1 (0.36) | PIK3CAMAT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3347361-B1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2020-08-05 | — | — | EP | disclosed |
| EP-3347361-B1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2020-08-05 | — | — | EP | disclosed |
| US-10435414-B2 | Tricyclic PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2019-10-08 | — | — | US | disclosed |
| US-10435414-B2 | Tricyclic PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2019-10-08 | — | — | US | disclosed |
| US-20180327420-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2018-11-15 | — | — | US | disclosed |
| US-10065970-B2 | Tricyclic PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2018-09-04 | — | — | US | disclosed |
| EP-3347361-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | H. Hoffnabb-La Roche Ag (CH) | 2018-07-18 | — | — | EP | disclosed |
| US-20180162873-A9 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180162873-A9 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180162873-A9 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180065983-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2018-03-08 | — | — | US | disclosed |
| US-20180065983-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2018-03-08 | — | — | US | disclosed |
| US-20180065983-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2018-03-08 | — | — | US | disclosed |
| WO-2017042182-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2017-03-16 | — | — | WO | disclosed |
| WO-2017042182-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2017-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10435414-B2 | Tricyclic PI3K inhibitor compounds and methods of use | PIK3CA, PIK3CD, PIK3CB | PIK3CA 1/4885PIK3CB 3/4885PIK3CG 4/4885 |
| US-20180065983-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CB | PIK3CA 1/4885PIK3CB 3/4885PIK3CG 4/4885 |
| US-20180162873-A9 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CB | PIK3CA 1/4885PIK3CB 3/4885PIK3CG 4/4885 |
| US-20180327420-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CB | PIK3CA 1/4885PIK3CB 3/4885PIK3CG 4/4885 |
| US-10065970-B2 | Tricyclic PI3K inhibitor compounds and methods of use | PIK3CA, PIK3CD, PIK3CB | PIK3CA 1/4885PIK3CB 3/4885PIK3CG 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.